Introduction {#s1}
============

An individual's emotional response to stress is determined by genetic and environmental factors. While most reactions to stressful events trigger adaptive changes to maintain normal psychological and physical functioning, their derailment could produce maladaptive behavioral responses leading to the development of major depressive disorders (MDD) ([@bib33]). It has been well recognized that medial prefrontal cortex (mPFC) plays a key role in controlling mood regulation. Changes in the morphology and/or function of mPFC neurons and local circuitry are well documented to contribute to the development of MDD ([@bib14]; [@bib50]). Studies in animal models indicate that loss of mPFC control drives anxiety- and depressive-like phenotypes ([@bib2]; [@bib54]), while treatments that act within the mPFC promote a therapeutic effect ([@bib29]). The molecular mechanisms underlying the pathology of MDD are complex and not fully understood but most models agree that they are related to abnormal processing of neurotransmitter signals most notably by the monoamine, GABA and glutamate systems ([@bib24]). It is thought that these changes occur as a result of maladaptive plasticity in response to several biological and environmental factors and that understanding the mechanisms behind this connection would be a prerequisite for the development of new therapeutic or prophylactic interventions.

Exposure to chronic stress is among the most powerful insulting factors that exerts significant negative effects on mood ([@bib31]). Exposure to stressful events is thought to underlie long-term neuroadaptations observed in MDD including dendritic remodeling, spine loss, and altered synaptic transmission ([@bib3]; [@bib47]). Much of these effects are mediated by the glucocorticoids whose unrestraint release during chronic stress often triggers development of maladaptive responses ([@bib37]). Glucocorticoids engage steroid receptors to initiate transcription of responsive genes responsible for lasting alterations in cellular function well beyond the time period of stress exposure ([@bib27]). However, the roles of stress-induced genes in mediating cellular changes in mPFC and driving maladaptive behavioral phenotypes are not well understood.

Several GPCRs have been implicated in the pathophysiology of MDD, as well as the effects of stress and pharmacological modulation of monoamine GPCRs is a mainstay practice in treating MDD ([@bib24]; [@bib55]). Still, therapeutic efficacy of available medications is limited, which is largely attributed to insufficient understanding of signaling cascades and neuronal circuits involved in modulating mood and stress responses, making identification of new players an attractive goal. In this study, we tap into the uncharted biology of orphan GPCR-like receptors screening for the novel stress-regulated genes in the mPFC. We identify the orphan receptor GPR158 as a key modulator of stress-induced depression. We show involvement of GPR158 in pathology of MDD in humans and demonstrate that manipulation with GPR158 in animal models produces antidepressive-like behaviors and stress resilience.

Results {#s2}
=======

Identification of GPR158 as a stress-inducible receptor modulated by glucocorticoids in the PFC {#s2-1}
-----------------------------------------------------------------------------------------------

With the intent of identifying novel players involved in the regulation of stress-mediated responses we focused our attention on orphan receptors, increasingly recognized for their potential ([@bib11]). We first defined the landscape of orphan receptors expressed in the brain by performing next generation sequencing of coding mRNAs, revealing that many orphan receptors are abundantly expressed in the mouse brain ([Figure 1A](#fig1){ref-type="fig"}). Subsequent proteomic profiling confirmed the expression of many of them specifically in the PFC ([Figure 1B](#fig1){ref-type="fig"}). We then analyzed the effect of chronic physical restraint stress (PRS) on the protein levels of several candidates from this list in the mPFC. Mice subjected to PRS revealed a significant upregulation in the levels of GPR158 ([Figure 1C](#fig1){ref-type="fig"}), coincidently amongst the most prominent GPCRs ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}) and, by far, the most abundant orphan receptor in the PFC ([Figure 1B](#fig1){ref-type="fig"}). PRS exposure did not affect GPR158 levels in other brain regions including the hippocampus, caudate-putamen or cerebellum ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). High-resolution in situ hybridization confirmed high expression levels of *Gpr158* message in the mPFC ([Figure 1D](#fig1){ref-type="fig"}). To evaluate the cell-type specific *Gpr158* expression pattern, we employed high-resolution double in situ hybridization with specific markers. We found *Gpr158* to be expressed in the majority of glutamatergic and in subpopulations of GABAergic neurons but largely absent in glia ([Figure 1---figure supplement 2A--D](#fig1s2){ref-type="fig"}).

![Stress upregulates GPR158 expression in the mPFC.\
(**A**) RNA sequencing results from the whole mouse brain showing the top 30 orphan receptors. (**B**) Mass spectrometry analysis of the orphan receptors expressed in the PFC of mice. (**C**) Representative western blots and protein level quantification of several orphan receptors identified in the mPFC of control non-stressed (Crtl) and mice subjected to chronic Physical Restraint Stress (PRS) (n = 4--5 mice/group; Student's t test; \*p\<0.05). (**D**) In situ hybridization showing the expression of GPR158 in the mPFC of mouse brain. (**E**) Mice subjected to PRS and unpredictable chronic mild stress (UCMS) show elevated GPR158 protein levels in the mPFC (n = 12--14 mice/group, one-way ANOVA with Bonferroni *post hoc* test). (**F**) Top panel shows scheme of stress paradigms. Graph showing a significant correlation between GPR158 protein levels and immobility in the TST of mice subjected to chronic stress (Pearson *R*^2^ = 0.6386, p\<0.0001). (**G**) Mice subjected to 1 day of physical resistant stress (Acute PRS, 3 hr, n = 6) show no difference in GPR158 protein levels compared to control non-stressed mice (Crtl, n = 8) in the mPFC.](elife-33273-fig1){#fig1}

Interestingly, in vitro studies implicated this receptor in the modulation of cellular signaling ([@bib39]; [@bib45]), while its close homolog, GPR179 is an established modulator of synaptic signaling in the retina ([@bib4]; [@bib46]) making it an interesting candidate to pursue. In support of an involvement of chronic stress in controlling GPR158 levels in the mPFC, we observed that a second stress paradigm, unpredictable chronic mild stress (UCMS), and an independent cohort of mice subjected to PRS showed, again, a significant upregulation of GPR158 ([Figure 1E](#fig1){ref-type="fig"}). Furthermore, a positive correlation between GPR158 levels in the mPFC and immobility in the tail suspension test was found in both models pointing to the involvement of GPR158 in stress behaviors ([Figure 1F](#fig1){ref-type="fig"}). In contrast, we found that mice subjected to acute PRS did not show a significant up-regulation of GPR158 protein levels in the mPFC ([Figure 1G](#fig1){ref-type="fig"}). Using immunohistochemistry to distinguish glutamatergic and GABAergic populations in combination with in situ hybridization using a probe against *Gpr158*, we quantified *Gpr158* mRNA levels in layer 2/3 of the mPFC. This approach revealed that PRS exposure selectively up-regulated *Gpr158* in the glutamatergic neurons but not in GABAergic neurons suggesting cell-specific modulation of GPR158-mediated effects ([Figure 2A--C](#fig2){ref-type="fig"}). Altogether we show that chronic stress induces overexpression of the orphan receptor GPR158 in glutamatergic neurons of the mPFC.

![Chronic stress regulates GPR158 levels in glutamatergic neurons of the layer 2/3 of the mPFC.\
(**A**) Representative image of in situ hybridization using a probe against GPR158 (yellow) and co-immunostaining with antibodies against NeuN (red) and GAD67 (green) in the layer 2/3 of mPFC (nuclei stained with DAPI in blue, scale bar = 50 µm). (**B**) Frequency distribution of GPR158 mRNA levels in glutamatergic neurons in the mPFC layer 2/3 (Ctrl n = 5 mice/6486 neurons; PRS n = 5 mice/6400 neurons; bin width = 10; p\<0.0001 Kolmogorov--Smirnov test). (**C**) Frequency distribution of GPR158 expression in GAD67- positive neurons (Ctrl n = 5 mice/569 cells; PRS n = 5 mice/564 cells; bin width = 10; p=0.9599 Kolmogorov-Smirnov test).](elife-33273-fig2){#fig2}

We next examined the effects of glucocorticoids on GPR158 levels, as they mediate the effects of chronic stress on gene expression ([@bib1]; [@bib22]). Chronic corticosterone administration elevated GPR158 protein expression in the mPFC and GPR158 levels correlated with the immobility time in the TST ([Figure 3A](#fig3){ref-type="fig"}). In contrast, acute injection of corticosterone did not affect GPR158 protein levels ([Figure 3B](#fig3){ref-type="fig"}). Furthermore, a 7 day treatment of primary cortical neurons with the glucocorticoid receptor agonist dexamethasone upregulated GPR158 expression ([Figure 3C](#fig3){ref-type="fig"}). Finally, we found that systemic administration of the glucocorticoid receptor antagonist, RU-486 blocked the increase in GPR158 expression induced by chronic stress in the mPFC ([Figure 3D](#fig3){ref-type="fig"}). Taken together with the presence of glucocorticoid responsive elements in the promoter of GPR158 gene and its regulation by glucocorticoids in peripheral cells ([@bib45]), these results suggest that chronic stress influences GPR158 protein levels via corticosteroid-induced regulation of GPR158 gene expression.

![GPR158 is increased in the mouse mPFC by a corticosterone-mediated mechanism.\
(**A**) GPR158 protein levels are increased in the mPFC of mice chronically treated with corticosterone (n = 9--10 mice/group, Student's *t* test). Top panel depicts corticosterone paradigm. Mice treated with corticosterone exhibited a significant correlation between GPR158 protein levels and immobility in the TST (Pearson *R*^2^ = 0.4605, p=0.0014). (**B**) Mice injected acutely with corticosteroid (Acute Cort., 20 mg/kg) show no difference in GPR158 levels compared to vehicle (Veh) treatment (n = 5, Student's *t* test; ns, not significant). (**C**) Western blot quantification of GPR158 in primary cortical neurons cultured for 21 days in vitro and treated with 0.5 µM dexamethasone (Dex) from DIV 14 to DIV21 (n = 3, Student's *t* test, \*p\<0.05). (**D**) GPR158 protein levels in the mPFC of mice subjected to physical restraint stress and treated with RU-486. To induce chronic stress mice underwent a 17 day PRS period. On the last three days of the stress paradigm, mice were injected with RU-486 (10 mg/kg) or vehicle prior to being subjected to PRS. The mPFC was isolated 30 min following last episode of PRS (day 17). Stressed mice treated with RU-486 have a decrease in GPR158 protein levels compared to saline treatment (n = 4--5 mice/group, Two-way ANOVA with Tukey post hoc test, \*\*p\<0.01, \*\*\*p\<0.001). Data shown as means ± SEM (Veh, vehicle; Ctrl, control; PRS, physical restraint stress; Cort., corticosterone).](elife-33273-fig3){#fig3}

GPR158 overexpression in mouse mPFC is sufficient to induce a depressive-like phenotype {#s2-2}
---------------------------------------------------------------------------------------

To investigate the role of increased GPR158 levels in depressive-like behaviors affected by stress, we utilized a viral approach to overexpress GPR158 in the mPFC ([Figure 4A and B](#fig4){ref-type="fig"}). Bilateral injections of GPR158-expressing viral vector (GPR158-Ad) but not control virus (EGFP-Ad) significantly elevated GPR158 expression in the region ([Figure 4C](#fig4){ref-type="fig"}). Strikingly, we found that mice given GPR158-Ad infusions displayed increased immobility in the tail suspension and forced swim tests while their behavior in the marble burying and elevated plus maze tests was unchanged relative to control group treated with EGFP-Ad ([Figure 4D--G](#fig4){ref-type="fig"}). To assess the overall consistency along similar behavioral dimensions and reduce the bias introduced by individual tests that probe different aspects related to mood and anxiety we additionally calculated an aggregate 'emotionality score' by meta-analysis of all behavioral data by z-scoring methodology ([@bib23]) ([Figure 4H](#fig4){ref-type="fig"}). This analysis further revealed that mice injected with GPR158-Ad had a higher emotionality score compared to EGFP-Ad mice indicating that elevating GPR158 levels in the mPFC is sufficient to induce depressive-like behaviors.

![GPR158 overexpression in mouse mPFC and in dlPFC of MDD patient.\
(**A**) Scheme of Punisher-Adenovirus expressing GPR158 (GPR158-Ad) and EGFP (EGFP-Ad) injected bilaterally into the mPFC of C57Bl/6J mice. (**B**) Representative viral expression in the mPFC (right panel). (**C**) Representative western blots and quantification of GPR158 protein levels of mice injected with GPR158-Ad and EGFP-Ad. Injected mice underwent marble burying test (**D**), Elevated Plus Maze (**E**), Tail Suspension Test (**F**), and Forced Swim Test (**G**) (n = 8 mice/group). (**H**) Emotionality scores were integrated from four behavioral tests (marble burying, elevated plus maze, tail suspension test and force swim test) and normalized to mice injected with EGFP-Ad. (**I**) Mice injected with GPR158-Ad showed a higher emotionality score reflective of a depressive-like phenotype. (**J**) Representative western blot and quantification of GPR158 protein levels in the dlPFC show an increase in subjects with MDD compared to healthy unaffected controls (Ctrl) (Ctrl n = 14; MDD n = 13). The different groups were matched as closely as possible for sex, age, and postmortem interval (see Materials and methods for further information). Data are mean ± SEM (Student's *t* test, \*p\<0.05, \*\*p\<0.01).](elife-33273-fig4){#fig4}

To assess the clinical relevance of GPR158 expression modulation, we analyzed GPR158 protein levels in the postmortem dorsolateral PFC (dlPFC) of subjects diagnosed with MDD. Western blot analysis revealed a significant elevation in GPR158 protein levels in the dlPFC of MDD patients compared to match controls ([Figure 4J](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), suggesting that this receptor may be involved in the neuropathology of depression.

Elimination of GPR158 in mice promotes an antidepressive-like phenotype {#s2-3}
-----------------------------------------------------------------------

To further test the function of GPR158 in vivo, we evaluated the behavior of mice lacking GPR158 expression (*Gpr158^−/−^*). *Gpr158^−/−^* animals showed attenuated response to stress-induced hyperthermia compared to their wild-type littermates, *Gpr158^+/+^* mice ([Figure 5A](#fig5){ref-type="fig"}), suggesting its involvement in stress-related behaviors. Male mice were evaluated in a panel of behavioral tests that assess various aspects of anxiety/depressive-like behaviors ([Figure 5B--E](#fig5){ref-type="fig"}). *Gpr158^−/−^* mice buried fewer marbles in the marble burying test ([Figure 5B](#fig5){ref-type="fig"}), spent more time and had more crossovers into the open arm in the elevated plus maze ([Figure 5C](#fig5){ref-type="fig"}), had reduced immobility in the tail suspension ([Figure 5D](#fig5){ref-type="fig"}) and forced swim tests ([Figure 5E](#fig5){ref-type="fig"}). Overall, the *Gpr158^−/−^* mice displayed a lower emotionality score compared to *Gpr158^+/+^* mice, corresponding to an anxiolytic and antidepressant-like phenotype ([Figure 5F](#fig5){ref-type="fig"}). These behavioral effects were specific as ablation of *Gpr158* did not affect overall behavioral reactions of mice including locomotor activity, habituation, motor coordination and learning ([Figure 5---figure supplement 1A--B](#fig5s1){ref-type="fig"}). Similarly, female *Gpr158^−/−^* mice also displayed a marked anxiolytic and antidepressant-like phenotype across behavioral tests demonstrating the behavioral effect due to the absence of GPR158 is independent of sex ([Figure 5---figure supplement 1C--G](#fig5s1){ref-type="fig"}). Furthermore, re-expression of GPR158 in the mPFC of adult *Gpr158^−/−^* mice by utilizing the GPR158-expressing viral vector (GPR158-Ad) restored the depressant-like phenotype as evidence by an increase in their emotionality score ([Figure 5---figure supplement 2A--F](#fig5s2){ref-type="fig"}).

![Ablation of GPR158 in mice results in an antidepressant-like phenotype and resiliency to chronic stress.\
(**A**) *Gpr158^−/−^* mice display a lower SIH response (T2--T1) compared to *Gpr158^+/+^* mice without affecting their baseline temperature (right panel) (n = 15--17/genotype, Student's t test, \*p\<0.05). (**B**) *Gpr158^−/−^* mice buried fewer marbles compared to *Gpr158^+/+^* mice in the marble burying test. (**C**) *Gpr158^−/−^* mice spent significantly more time in the open arm and entered more frequently in the open arm during the EPM test. *Gpr158^−/−^* mice displayed decreased immobility time in the (**D**) TST and (**E**) FST. (**F**) Emotionality scores were integrated from four behavioral tests (marble burying, elevated plus maze, tail suspension test and force swim test) and normalized to *Gpr158^+/+^* mice. (**G**) *Gpr158^−/−^* mice had a lower emotionality score reflective of an antidepressant-like phenotype (right panel; Student's *t* test). Data shown as means ± SEM (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001; ns = not significant).](elife-33273-fig5){#fig5}

To further explore the role of GPR158 in stress-induced depression we utilized the UCMS model. As expected, *Gpr158^+/+^* mice exposed to UCMS buried significantly more marbles in the marble burying test ([Figure 6A](#fig6){ref-type="fig"}), spent more time and had more crossovers into the open arm in the elevated plus maze ([Figure 6B](#fig6){ref-type="fig"}), exhibited increased immobility in the tail suspension ([Figure 6C](#fig6){ref-type="fig"}) and forced swim tests ([Figure 6D](#fig6){ref-type="fig"}). Together, *Gpr158^+/+^* mice that underwent UCMS displayed a higher emotionality score, consistent with the induction of a depressive-like state ([Figure 6E](#fig6){ref-type="fig"}). In contrast, *Gpr158^−/−^* mice were unaffected by UCMS, demonstrating a resiliency to chronic stress ([Figure 6A--E](#fig6){ref-type="fig"}). Furthermore, UCMS significantly reduced sucrose preference in *Gpr158^+/+^* mice but had no effect on *Gpr158^−/−^* mice demonstrating their resilience to stress-induced anhedonia ([Figure 6F](#fig6){ref-type="fig"}). Together, these results indicate the involvement of GPR158 in the control of stress-induced depression.

![*Gpr158^−/−^* mice are resilient to unpredictable chronic mild stress (UCMS).\
Individual behavioral measures were integrated to calculate the emotionality score for each animal. Behavioral analysis of *Gpr158^+/+^* and *Gpr158^−/−^* mice subjected to UCMS in the (**A**) marble burying test, (**B**) elevated plus maze (EPM), (**C**) tail suspension test (TST) and (**D**) forced swim test (FST). (**E**) Emotionality score and (**F**) sucrose preference test for *Gpr158^+/+^* and *Gpr158^−/−^* mice subjected to UCMS (n = 15--20 mice/group, Two-way ANOVA with Bonferroni post hoc test). Data shown as means ± SEM (n = 15--20 mice/group; Two-way ANOVA with Bonferroni post hoc; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001; ns, not significant).](elife-33273-fig6){#fig6}

GPR158 loss induces synaptic adaptations {#s2-4}
----------------------------------------

To explore the mechanisms underlying the antidepressant-like effect associated with the elimination of GPR158 we first focused on examining changes in neuronal morphology. A morphological analysis of the glutamatergic neurons in the layers 2/3 of the prelimbic PFC revealed a 25% increase in spine density in *Gpr158^−/−^* mice compared to *Gpr158^+/+^* littermates ([Figure 7A](#fig7){ref-type="fig"}). Consistent with the observed increase in spine density, patch-clamp electrophysiological recordings revealed an increase in frequency of spontaneous excitatory post-synaptic currents (sEPSC) in the same neuronal population ([Figure 7B and C](#fig7){ref-type="fig"}). There were no significant changes in sEPSC amplitude ([Figure 7D](#fig7){ref-type="fig"}) and paired-pulse ratio (PPR) ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}) suggesting the postsynaptic nature of this effect ([@bib59]).

![Synaptic adaptations in layer 2/3 neurons of mPFC induced by GPR158 loss.\
(**A**) Representative images and summarized data showing that the spine density was increased in *Gpr158^−/−^* neurons (n = 7--5). (**B**) Representative traces and summarized data showing that the frequency (**C**) (n = 8--6 mice/genotype; Student's *t* test), but not the amplitude (**D**) (n = 8--6 mice/genotype; Student's *t* test), of sEPSC was increased in *Gpr158^−/−^* neurons. (**E**) Representative traces and summarized data showing that AMPAR/NMDAR current ratio was increased in *Gpr158^−/−^* neurons (n = 6--7 mice/genotype). The AMPAR component was measured as the maximal response while neurons were held at −70 mV. The NMDAR component was measured as the average current between 50--55 ms (square) following the stimulation while the neurons were held at +40 mV. (**F**) Representative image of a spine and dendrite showing location of glutamate uncaging. (**G**) AMPAR- and NMDAR-mediated uEPSCs at −65 and +40 mV, respectively. The green dotted line (70 ms after uncaging pulse) indicates the time at which the NMDAR-uEPSCs were measured. Summary of (**H**) AMPAR uEPSC (n = 47--48 neurons/genotype) and (**I**) NMDAR uEPSC (n = 40--47 neurons/genotype) amplitude are shown for each genotype. (**J**) FST for *Gpr158^−/−^* and *Gpr158^+/+^* mice injected with NBQX (**K**) Representative western blots and quantification of total and phosphorylated levels of AMPAR subunits, GluA1 and GluA2 (n = 4--6). (**L**) Basal levels of cAMP in the mPFC of *Gpr158^+/+^* and *Gpr158^−/−^* mice (n = 4--8 mice/genotype). Data are mean ± SEM (Student's *t* test, \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001, ns = not significant).](elife-33273-fig7){#fig7}

We next determined the contribution of the AMPA and NMDA receptors to the generation of the postsynaptic response in layer 2/3 glutamatergic neurons because of their significant contributions to structural spine dynamics ([@bib56]) and antidepressant effects ([@bib5]). We found that the ratio of AMPAR to NMDAR components was significantly elevated in *Gpr158^−/−^* indicating that loss of GPR158 leads to an increase in the synaptic strength ([Figure 7E](#fig7){ref-type="fig"}).

To identify which receptor accounts for this effect, we performed glutamate uncaging experiments at single spines while measuring the currents mediated by each of the receptors individually ([Figure 7F--G](#fig7){ref-type="fig"}). These experiments revealed significantly elevated amplitude of the AMPAR responses in *Gpr158^−/−^* neurons ([Figure 7H](#fig7){ref-type="fig"}) with no significant changes in NMDAR function ([Figure 7I](#fig7){ref-type="fig"}). The effect persisted regardless of the size of the dendritic spine being analyzed ([Figure 7---figure supplement 1B--C](#fig7s1){ref-type="fig"}). Accordingly, treatment with the AMPAR blocker NBQX reverted the antidepressant-like phenotype in *Gpr158^−/−^* mice but did not affect *Gpr158^+/+^* mice in the FST ([Figure 7J](#fig7){ref-type="fig"}). Notably, we also found an increase in the levels of GluA2 and in the phosphorylation of GluA1 at Ser845 in mPFC of *Gpr158^−/−^* mice ([Figure 7K](#fig7){ref-type="fig"}), but no changes in total or phosphorylated NMDAR subunits were found (NR1, NR2B; [Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). Considering that the phosphorylation at the Ser845 of GluA1 is mediated by PKA ([@bib51]), we hypothesized that GPR158 may exert its effects through cAMP. Consistent with this expectation, we found significantly higher levels of cAMP in the mPFC of *Gpr158^−/−^* mice ([Figure 7L](#fig7){ref-type="fig"}).

To investigate the molecular basis behind the cellular adaptations and antidepressant-like phenotype we screened for changes in several signaling proteins induced by GPR158 loss in the mPFC ([Figure 8A--B](#fig8){ref-type="fig"}). Remarkably, we found a substantial increase in the levels of brain derived neurotrophic factor (BDNF) ([Figure 8B](#fig8){ref-type="fig"}), a hallmark feature thought to mediate the effects of antidepressants and their effects on spine morphology ([@bib15]) ([@bib7]). This result was replicated on new cohort of mice ([Figure 8C](#fig8){ref-type="fig"}). Addressing the mechanisms involved we found no change in *Bdnf* mRNA levels but we observed a decrease in the phosphorylation level of the eukaryotic elongation factor 2 (eEF2), suggesting that the increase BDNF levels in *Gpr158^−/−^* mPFC may be due to local synthesis ([Figure 8D--E](#fig8){ref-type="fig"}). Finally, we found no change in monoamine neurotransmitter levels, or turnover, in the mPFC region of *Gpr158^−/−^* mice ([Figure 8F--G](#fig8){ref-type="fig"}), indicating that the behavioral effects observed in *Gpr158^−/−^* mice are due to alterations in receptor signaling mechanisms rather than effects on neurotransmitter activity. Overall, these results indicate that behavioral changes induced by GPR158 loss are paralleled by synaptic adaptations that potentiate structural and functional state of synapses.

![GPR158 modulates BDNF protein levels in the mPFC.\
Representative western blots (**A**) and quantification (**B**) of the protein levels and phosphorylation state of the indicated proteins in the mPFC of *Gpr158^+/+^* and *Gpr158^−/−^* mice (n = 4--6). (**C**) Western blot quantification of BDNF levels in the mPFC of *Gpr158^+/+^* and *Gpr158^−/−^* mice (n = 6). (**D**) Comparison of mRNA levels of 4 BDNF splicing isoforms in the mPFC of *Gpr158^+/+^* and *Gpr158^−/−^* do not show any significant difference. GPR158 levels were normalized against the ribosomal subunit 18S RNA (n = 7). (**E**) Western blot and quantification of total and phosphorylated levels of eEF2 (n = 5--6). (**F**) Quantitative analysis of the levels of norepinephrine (NE), 3-methoxy-4-hydroxyphenylglycol (MHPG), 3,4-dihydroxyphenylacetic acid (DOPAC), dopamine (DA), 5-hydroxyindoleacetic acid (5HIAA), homovanillic acid (HVA) and serotonin (5HT) in the mPFC of *Gpr158^+/+^* and *Gpr158^−/−^* (**G**) Neurotransmitter turnover calculated as metabolite/neurotransmitter ratio. Data are mean ± SEM (Student's *t* test, \*p\<0.05, \*\*\*p\<0.001).](elife-33273-fig8){#fig8}

Discussion {#s3}
==========

In this study, we identify the orphan receptor GPR158 as a critical regulator of behavioral responses to stress. Since stress is a significant risk factor for MDD, understanding the cellular and molecular factors underlying behavioral vulnerability or resilience to stress-induced behavioral responses is poised to shed light on mechanisms of MDD initiation and progression. Several lines of evidence obtained in this study suggest that orphan receptor GPR158 may be one of the key molecular factors determining an individual's susceptibility or resiliency to stress-induced depression. The vast majority of evidence was obtained studying responses of mice to stress-induced depression, validated to model salient features of MDD including anhedonia, anxiety-like behaviors and physiological changes ([@bib12]; [@bib17]). We found that suppression of GPR158 produced an antidepressant-like phenotype and promoted a resiliency to stress. In contrast, induction of GPR158 induced a depressive-like effect. In addition to these causative effects, we found a strong correlation between levels of GPR158 and the emotional state of the animal in a way serving as a 'biomarker' of maladaptive responses. Notably, this relationship was further observed in humans where subjects diagnosed with MDD were found to also have elevated GPR158 levels as compared to unaffected individuals, although it is unknown if stress was a contributing factor. Mechanistically, stress induces changes in GPR158 expression via glucocorticoids. It is well established that prolonged glucocorticoid release precipitated by chronic stress leads to changes in transcription of multiple genes through direct engagement of nuclear receptor complexes and that this regulation plays a key role in the long-term structural and functional changes associated with mood disorders ([@bib43]; [@bib53]; [@bib61]). Accordingly, we found that GPR158 upregulation requires sustained corticosteroid elevation induced by chronic but not acute stress exposure. Such differential sensitivity is thought to be underpinned by several mechanisms including epigenetic control and feedback at the glucocorticoid receptors ([@bib25]). Together, these findings make GPR158 bona fide glucocorticoid responsive gene in the brain.

Anatomically, we pinpoint that GPR158 exerts its effects on depressive-like behaviors in mPFC. Although the involvement of other regions in mediating the actions of GPR158 on depression-like and stress related behaviors cannot be ruled out, its effects in PFC appear to be sufficient for driving behavioral changes supported by both gain and loss of function experiments. Given GPR158 broad expression pattern throughout the brain, this orphan receptor may be involved in regulating other physiological functions. As such, GPR158 has been shown to play a role in hippocampal-memory function, a process mediated by osteocalcin ([@bib28]). At this time, it is unknown if osteocalcin is involved in mediating the effects of GPR158 in stress-induced depression and further investigation is warranted. It is unclear whether osteocalcin is the only endogenous ligand of GPR158 across the entire brain or whether different ligands may be involved on modulation GPR158 activity in a region-specific manner. The latter possibility appears to be possible given that signaling changes that we observe in the PFC neurons are consistent with GPR158 serving as an inhibitory GPCR as opposed to Gq-coupled excitatory action in the hippocampus. In any event, it is clear that changes in the levels of GPR158 in the mPFC contribute to modulation of emotionality responses. Intriguingly, the mPFC is a key region targeted by stress hormones, including glucocorticoids and that stress-induced changes in mPFC are firmly linked to neuroendocrine and behavioral responses to stress. Manipulation of glutamatergic neurons in the mPFC have been shown to control behavioral responses to stressful events ([@bib29]; [@bib52]; [@bib54]), while optogenetic stimulation induced an antidepressant-like response ([@bib12]; [@bib19]). Studies in animal models indicate that loss of mPFC control drives anxiety- and depressive-like phenotypes ([@bib2]; [@bib54]), while treatments that act within the mPFC promote a therapeutic effect ([@bib29]). Furthermore, we provide evidence that within PFC, GPR158 modulates properties of the glutamatergic neurons in layer 2/3. Intriguingly, recent studies provide strong support for a role of layer 2/3 in the PFC in stress and depression. Stress-induced depression was documented to reduce spine densities and branch points in layer 2/3 of the mPFC ([@bib48]; [@bib49]) whereas activation of their subpopulation induced rapid and distinct changes in depression-like behaviors ([@bib58]). Given that these neurons innervate various limbic and brainstem structures, and serve as the main projections for intracortical communication ([@bib20]) it seems possible that modulation of stress and depression-like behaviors by GPR158 to some extent involves its effects on layer 2/3 neurons.

At the cellular level, we determined that GPR158 exerts its effects by profoundly influencing the synaptic strength. These changes are evident at both the structural and functional level as reflected by increase in spine density and enhanced AMPAR/NMDAR ratio, respectively. We found that these changes are largely attributed to an increase in postsynaptic AMPAR function due to an increase in both GluA2 expression and GluA1 phosphorylation at Ser845 which increases its content on the surface ([@bib18]) and synaptic strength ([@bib32]). Accordingly, our findings establish GPR158 as a critical negative regulator of synaptic strength, which is likely mediating its cellular and behavioral effects. In addition, to the direct functional effects on processing synaptic inputs, increase in AMPAR signaling has been also shown to increase the expression of key neurotrophic factor BDNF via local protein synthesis ([@bib26]; [@bib63]). Although the actions of BDNF are complex and not fully understood, it is thought to further exert anti-depressant effects through structural alterations, transcriptional and epigenetic changes ([@bib8]). Accordingly, our findings establish GPR158 as a critical negative regulator of both synaptic strength and BDNF production, which are likely key effector systems mediating its cellular and behavioral effects. Several lines of evidence support the role of synaptic adaptations and AMPAR function in depression, stress and the development of MDD. For example, reduction in AMPA receptor-dependent synaptic responses in the PFC has been observed in models of stress-induced depression ([@bib62]). Conversely, ketamine and its metabolites exert rapid and powerful antidepressant effects in animal models of depression ([@bib5]; [@bib44]) and in humans ([@bib64]) by increasing synaptic strength defined as upregulation in AMPAR/NMDAR ratio by either blocking NMDAR function ([@bib34]) or augmenting AMPAR activity ([@bib63]), respectively. In accordance with our GPR158 results, the antidepressant effects of ketamine or traditional antidepressant medication is blocked by the inhibition of AMPAR ([@bib21]; [@bib65]). Finally, chronic treatments with typical antidepressants have been shown to affect AMPA receptor levels in the PFC ([@bib6]). The increased cAMP levels observed in the mPFC of *Gpr158^−/−^* mice suggest that cAMP-dependent PKA activation may be responsible for the increased phosphorylation of GluA1. Thus, GPR158 may function at the critical nexus of stress, depression, and synaptic plasticity linking these processes at the molecular level.

In summary, our data demonstrates that GPR158 plays a prominent role in the regulation of stress-induced depression via adaptations in synaptic plasticity. These findings implicate GPR158 signaling in the pathophysiology of depression and identify a new therapeutic target to block or reverse the effects of chronic stress and depressive behaviors.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\                    Designation                                          Source or reference                                                                                                                         Identifiers                                                                                                                                                                                     Additional\
  or resource                                                                                                                                                                                                                                                                                                                                                                                                                                 information
  ------------------------------------------ ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  Antibody                                   GAPDH                                                Millipore                                                                                                                                   Cat\# AB2302                                                                                                                                                                                    (1:30000)

  Antibody                                   GluA1                                                Abcam                                                                                                                                       Cat\# ab76321                                                                                                                                                                                   (1:1000)

  Antibody                                   p831 GluA1                                           Millipore                                                                                                                                   Cat\# 04--823                                                                                                                                                                                   (1:1000)

  Antibody                                   p845 GluA1                                           Cell Signaling                                                                                                                              Cat\# 8084                                                                                                                                                                                      (1:1000)

  Antibody                                   GluA2                                                Millipore                                                                                                                                   Cat\# MAB N71                                                                                                                                                                                   (1:1000)

  Antibody                                   NR1                                                  Zymed                                                                                                                                       Cat\# 32--500                                                                                                                                                                                   (1:1000)

  Antibody                                   p897 NR1                                             Millipore                                                                                                                                   Cat\# 06--641                                                                                                                                                                                   (1:1000)

  Antibody                                   NR2B                                                 Millipore                                                                                                                                   Cat\# AB1557P                                                                                                                                                                                   (1:1000)

  Antibody                                   Rabbit anti-GPR158CT                                 PMID:25792749                                                                                                                               N/A                                                                                                                                                                                             (1:1000)

  Antibody                                   Rabbit anti-Gβ5                                      PMID:15632198                                                                                                                               N/A                                                                                                                                                                                             (1:1000)

  Antibody                                   Rabbit anti-Gβ1                                      gift from Dr. Willardson PMID:15485848                                                                                                      N/A                                                                                                                                                                                             1:6000

  Antibody                                   GPR34                                                ThermoFisher Scientific                                                                                                                     Cat\# PA5-45717                                                                                                                                                                                 (1:1000)

  Antibody                                   GPR162                                               Aviva Systems Biology                                                                                                                       Cat\# ARP68400                                                                                                                                                                                  (1:1000)

  Antibody                                   GPRC5B                                               Aviva Systems Biology                                                                                                                       Cat\# ARP59799                                                                                                                                                                                  (1:1000)

  Antibody                                   AKT                                                  Cell Signaling                                                                                                                              Cat\# 9272                                                                                                                                                                                      (1:1000)

  Antibody                                   p473 AKT                                             Cell Signaling                                                                                                                              Cat\# 4060                                                                                                                                                                                      (1:1000)

  Antibody                                   mTOR                                                 Cell Signaling                                                                                                                              Cat\# 2983                                                                                                                                                                                      (1:1000)

  Antibody                                   S6 Kinase (P70)                                      Cell Signaling                                                                                                                              Cat\# 9202                                                                                                                                                                                      (1:1000)

  Antibody                                   ERK1/2                                               Cell Signaling                                                                                                                              Cat\# 9102                                                                                                                                                                                      (1:1000)

  Antibody                                   GSK-3β                                               Cell Signaling                                                                                                                              Cat\# 9315                                                                                                                                                                                      (1:1000)

  Antibody                                   p9 GSK3α/β                                           Cell Signaling                                                                                                                              Cat\# 9331                                                                                                                                                                                      (1:1000)

  Antibody                                   BDNF                                                 Abcam                                                                                                                                       Cat\# ab108319                                                                                                                                                                                  (1:1000)

  Antibody                                   TrkB                                                 Cell Signaling                                                                                                                              Cat\# 4603                                                                                                                                                                                      (1:1000)

  Antibody                                   MeCP2                                                Millipore                                                                                                                                   Cat\# 07--013                                                                                                                                                                                   (1:1000)

  Antibody                                   Gαo                                                  Cell Signaling                                                                                                                              Cat\# 3975                                                                                                                                                                                      (1:1000)

  Antibody                                   PLCβ2                                                Santa Cruz                                                                                                                                  Cat\# sc206                                                                                                                                                                                     (1:200)

  Antibody                                   PP2Acat                                              Assay Biotech                                                                                                                               Cat\# B0555                                                                                                                                                                                     (1:1000)

  Antibody                                   PP2Areg                                              Cell Signaling                                                                                                                              Cat\# 2041                                                                                                                                                                                      (1:1000)

  Antibody                                   SYP                                                  Assay Biotech                                                                                                                               Cat\# C0333                                                                                                                                                                                     (1:1000)

  Antibody                                   PSD95                                                Cell Signaling                                                                                                                              Cat\# 3450                                                                                                                                                                                      (1:1000)

  Antibody                                   eEF2                                                 Cell Signaling                                                                                                                              Cat\# 2332                                                                                                                                                                                      (1:1000)

  Antibody                                   p56 eEF2                                             Cell Signaling                                                                                                                              Cat\# 2331                                                                                                                                                                                      (1:1000)

  Antibody                                   NeuN                                                 Abcam                                                                                                                                       Cat\# 104225                                                                                                                                                                                    (1:1000)

  Antibody                                   GAD67                                                Millipore                                                                                                                                   Cat\# MAB5406                                                                                                                                                                                   (1:1000)

  Genetic reagent (adenovirus)               HdAd-23E4-Pun-GPR158-syn-EGFP                        This Paper                                                                                                                                  N/A                                                                                                                                                                                             

  Genetic reagent (adenovirus)               HdAd-23E4-Pun-Syn-EGFP                               This Paper                                                                                                                                  N/A                                                                                                                                                                                             

  Biological sample (brain tissue)           Adult human brain tissue (healthy and MDD samples)   NIH NeuroBioBank (University of Pittsburg, University of Miami Brain Endowment Bank and the Human Brain and Spinal Fluid Resource Center)   13138, 13054, 13082, 5289, 002, 006, 5293, AN04642, AN04917, AN07465, AN14368, AN15392, AN01077, AN05364, 13006, 13011, 13022, 13047, 13075, 13086, 13145, 13057, 13051, 13181, 535, 556, 711   

  Chemical compound, drug                    Corticosterone                                       Sigma-Aldridge                                                                                                                              Cat\# C2505                                                                                                                                                                                     

  Chemical compound, drug                    RU-486                                               Sigma-Aldridge                                                                                                                              Cat\# M8046                                                                                                                                                                                     

  Chemical compound, drug                    Dexamethasone                                        Tocris                                                                                                                                      Cat\# D4902                                                                                                                                                                                     

  Chemical compound, drug                    NBQX                                                 Tocris                                                                                                                                      Cat\# 10441R                                                                                                                                                                                    

  commercial assay or kit                    QuantiGene ViewRNA ISH Tissue 2-Plex Assay           Affymetrix                                                                                                                                  Cat\# QVT0012                                                                                                                                                                                   

  commercial assay or kit                    *Gpr158* NM_001004761; ViewRNA TYPE 1 Probe          Affymetrix                                                                                                                                  Cat\# VB1-11518                                                                                                                                                                                 

  commercial assay or kit                    Slc17a7 NM \_182993; ViewRNA TYPE 6 Probe            Affymetrix                                                                                                                                  Cat\# VB6-14162                                                                                                                                                                                 

  commercial assay or kit                    *Gad1* NM_008077; ViewRNA TYPE 6 Probe               Affymetrix                                                                                                                                  Cat\# VB6-12632                                                                                                                                                                                 

  commercial assay or kit                    *Pvalb* NM_013645; ViewRNA TYPE 6 Probe              Affymetrix                                                                                                                                  Cat\# VB6-13220                                                                                                                                                                                 

  commercial assay or kit                    *Sst* NM_009215; ViewRNA TYPE 6 Probe                Affymetrix                                                                                                                                  *Cat\# VB6-13754*                                                                                                                                                                               

  commercial assay or kit                    *DapB* NC_000913; ViewRNA TYPE 1 Probe               Affymetrix                                                                                                                                  Cat\# VF1-10272                                                                                                                                                                                 

  commercial assay or kit                    Direct cAMP ELISA kit                                ENZO Life Sciences                                                                                                                          Cat\# ADI-900--066                                                                                                                                                                              

  strain, strain background (mus musculus)   GPR158 KO                                            PMID:25792749                                                                                                                               N/A                                                                                                                                                                                             

  software, algorithm                        ImageJ                                               Wayne Rasband, NIH, USA                                                                                                                     SCR_003070                                                                                                                                                                                      

  software, algorithm                        Zen2.1 SP1 (Black)                                   Carl Zeiss                                                                                                                                  SCR_013672                                                                                                                                                                                      

  software, algorithm                        Prism6                                               GraphPad Software                                                                                                                           SCR_002798                                                                                                                                                                                      

  software, algorithm                        Neurolucida                                          MBF Bioscience                                                                                                                                                                                                                                                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Experimental models and subject details {#s4-1}
---------------------------------------

All studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) protocol (\#16--032) at The Scripps Research Institute. The *Gpr158^−/−^* mice were purchased from KOMP (*Gpr158^tm1(KOMP)Vlcg^*) and maintained on a C57/Bl6 background. They were breed as heterozygous breeding pairs to generate *Gpr158^−/−^* and *Gpr158^+/+^* littermates. C57Bl/6J mice were used in biochemical and behavioral experiments using stress-induced paradigms described below. We relied exclusively on littermates for all the comparisons. Mice were housed in groups (unless otherwise stated) on a 12 hr light-dark cycle with food and water available *ad libitum*. Both male and female *Gpr158^−/−^* mice were used to assess emotionality. Male mice were used in all other behavioral assays, while both male and female were used for biochemistry analysis, and were between 2--5 months of age.

Antibodies and western blots {#s4-2}
----------------------------

For western blot analysis, brains were quickly removed from euthanized mice and medial prefrontal cortex was excised with a 3 mm puncher. Tissues were lysed in ice-cold lysis buffer (300 mM NaCl, 50 mM Tris-HCl pH 7.4, 1% Triton X-100, complete protease inhibitor cocktail (Roche Applied Science, Penzberg, Germany) and phosphatase inhibitor mix (Sigma-Aldrich, St. Louis, MO) by sonication, incubated on a rocker for 30 min at 4°C and cleared by centrifugation at 14,000 rpm for 15 min. The supernatant was saved and the protein concentration was obtained using Pierce 660 nm Protein Assay (Thermo Fisher, Waltham, MA). Samples were diluted in 4 × SDS sample buffer and analyzed by SDS-PAGE. Researcher was blinded to the genotype/treatment history of the samples.

The generation of rabbit antibodies against Gpr158CT was described earlier ([@bib40]). Rabbit anti-Gβ1 was a kind gift from Dr. Barry Willardson (Brigham Young University, Provo, Utah). The following antibodies used for western blot were purchased: GPR34 (Thermo; PA5-45717); GPR162 (Aviva; ARP68400); GPRC5b (Aviva; ARP59799); GAPDH (Millipore; MAB374); AKT (Cell Signaling; 9272); p473 AKT (Cell Signaling; 4060); mTOR (Cell Signaling; 2983); S6 Kinase (P70) (Cell Signaling; 9202); ERK1/2 (Cell Signaling; 9102); GSK-3β (Cell Signaling; 9315); p9 GSK3α/β (Cell Signaling; 9331); BDNF (Abcam; ab108319); TrkB (Cell Signaling; 4603); MeCP2 (Millipore; 07--013); Gαo (Cell Signaling; 3975); PLCβ2 (Santa Cruz; sc206); PP2Acat (Assay Biotech; B0555); PP2Areg (Cell Signaling; 2041); GluA1 (Abcam; ab76321); p831 GluA1 (Millipore; 04--823); p845 GluA1 (Cell Signaling; 8084); GluA2 (Millipore; MAB N71); NR1 (Zymed; 32--500); p897 NR1 (Millipore; 06--641); NR2B (Millipore; AB1557P); SYP (Assay Biotech; C0333); PSD95 (Cell Signaling; 3450); eEF2 (Cell Signaling; 2332); p56 eEF2 (Cell Signaling; 2331). The following antibodies used for immunohistochemistry were purchased: NeuN (Abcam; 104225); GAD67 (Millipore; MAB5406).

Primary cortical cultures {#s4-3}
-------------------------

Mouse cerebral cortices were extracted from neonatal P0-1 pups and placed into an ice-cold HBSS/FBS solution: Hank's Balanced Salt Solution (Sigma, St. Louis, MO), 4.2 mM NaHCO~3~, 1 mM HEPES, and 20% FBS. The tissue was washed three times with HBSS and then digested at 37°C/15 min with Papain (Worthington Biochemical, Lakewood) in a solution that contained 137 mM NaCl, 5 mM KCl, 7 mM Na~2~HPO~4~, and 25 mM HEPES (pH 7.2). The tissue was washed 3 times with 20% FBS, three times with HBSS, and three times with growth medium containing Neurobasal A, B27, Glutamax and Penicillin/Streptomycin (Invitrogen, Carlsbad, CA). Tissue was then triturated in growth medium containing 50 units of DNAse I (Invitrogen, Carlsbad, CA). The neurons were pelleted by centrifugation (600 × g for 10 min) and plated at a density of 40,000 cells/cm^2^ on poly-D-lysine-coated (Sigma-Aldrich, St. Louis, MO) 60 mm dishes. Neurons were incubated at 37°C/5% CO~2~, and half of the medium was replaced with fresh medium once a week. 0.5 µM dexamethasone (Sigma-Aldrich, St. Louis, MO) or vehicle (EtOH) was applied after 14 days in culture for 7 days.

In situ hybridization and immunohistochemistry {#s4-4}
----------------------------------------------

The mRNA expression of *Gpr158* was evaluated with ViewRNA^TM^ 2-plex In Situ Hybridization Assay (Panomics, Santa Clara, CA) using the following probe sets: *Gpr158* (NM_001004761; Cat\# VB1-11518), *vGlut1* (NM \_182993; Cat\# VB6-14162), *Gad1* (NM_008077; Cat\# VB6-12632), *Pvalb* (NM_013645; Cat\# VB6-13220), *Sst* (NM_009215; Cat\# VB6-13754). A probe against the E. Coli gene *DapB* (NC_000913; Cat\# VF1-10272) was used as specificity control as recommended by manufacturer. Briefly, mouse brains were embedded in OCT, flash frozen in liquid nitrogen, cut in 14 µm coronal sections and rapidly fixed in 4% paraformaldehyde for 10 min. Sections were then washed and incubated for 2 hr/RT in pre-hybridization mix (50% deionized formamide, 5X SSC, 5X Denhardt's solution, 250 μg/mL yeast tRNA, 500 μg/mL sonicated salmon sperm DNA), followed by overnight incubation at 40°C with Panomics hybridization solution containing TYPE one and TYPE 6 QuantiGene ViewRNA probe sets diluted 1:100. Sections were then processed according to manufacturer's instructions. To identify the soma of the cells, each section was counterstained with NeuroTrace 435/455 Blue Fluorescent Nissl Stain (1:100, Molecular Probes, Eugene OR) and mounted using Fluoromont-G (Southern Biotech, Birmingham, AL). When immunohistochemistry was performed in combination with in situ hybridization, the same protocol was followed without Nissl staining. AlexaFluor-488 and AlexaFluor-546-conjugated secondary antibodies (1:1000) were purchased from Invitrogen. DAPI was used for nuclear labeling.

All the images were acquired at The Light Microscopy Facility, the Max Planck Florida Institute, using on a LSM 780 Zeiss confocal microscope. Image acquisition and processing were accomplished using ZEN 2011 software (Carl Zeiss, Oberkochen, Germany) with only minor manipulations of the images setting the fluorescence intensity in non-saturating conditions and maintaining similar parameters for each acquired image.

RNA extraction and quantitative Real-Time PCR {#s4-5}
---------------------------------------------

Total RNAs from mouse medial prefrontal cortex were extracted using Trizol reagent according to the manual (Invitrogen, Carlsbad, CA). The RNA present in the aqueous phase was further purified using RNeasy kit (Qiagen, Hilden, Germany). Reverse transcription was carried out using qScript cDNA Supermix (Quantabio, Beverly, MA) according to manufacturer's instructions using 700 ng of total RNA. The reaction mixture was incubated at 25°C for 5 min, at 42°C for 30 min and then the enzyme was inactivated at 85°C for 5 min. Real-time PCR was performed with StepOne Real-time PCR system (Applied Biosystems, Foster City, CA) using SYBR Green (Roche Diagnostics, Indianapolis, IN). Relative expression levels were calculated by the comparative CT method and normalized to 18S ribosomal RNA. As reported ([@bib57]), RT-PCR primers used were:

*Bdnf* Exon I Forward: ACTGAGTCTCCAGGACAGCAAAG; Exon II Forward: GTGGTGTAAGCCGCAAAGAA; Exon IV Forward: CAGAGCAGCTGCCTTGATGTT;

Exon VI: CAGAAGCGTGACAACAATGTGA; common *Bdnf* Reverse: CCTTCATGCAACCGAAGTATGA. 18S Forward: ACCGCAGCTAGGAATAATGGA;

18S Reverse: GCCTCAGTTCCGAAAACCA.

RNA sequencing {#s4-6}
--------------

The 100 bp reads were generated by the HISeq Analyzer 2000 at the Scripps DNA Sequencing Facility. The Genome Analyzer Pipeline Software (Casava v1.8.2) was used to perform the early data analysis of a sequencing run, which does the image analysis, base calling, and demultiplexing. For RNA-Seq TopHat was used for alignment to the Mus_musculus genome Build mm10. For the mRNA gene annotation, Partek software, version 6.6 (Partek Inc., St. Louis, MO, USA) was used. The number of aligned reads for the three brain samples analyzed was \~30 million reads. These data were filtered to exclude transcripts for which the maximum number of reads for all samples was \<40 reads eliminating noise and calculated infinite fold-changes. Normalization was performed by the TMM (trimmed mean of M) method where the sample whose 75%-ile (of library-scale-scaled counts) is closest to the mean of 75%-iles as the reference. This adjustment was applied to the library size (total sample counts) to account for the compositional bias.

Mass spectrometry analysis {#s4-7}
--------------------------

The protein samples were subjected to concentrating SDS-PAGE at 120 V for 13 min. The unique gel band obtained was visualized by Coomassie staining (GelCode Blue Stain Reagent, Thermo Scientific, Waltham, MA) for 1 hr at room temperature with constant shacking, followed by water destaining overnight, and then cut into small gel pieces and submitted to in-gel trypsin digestion. Briefly, the gel pieces were treated with 10 mM DTT followed 50 mM iodoacetamide at pH 8.0 prior tryptic digestion (Promega, Madison, WI) overnight at 37°C. The resulting peptide pool was acidified and desalted onto Oasis C18 HLB extraction cartridges (Waters, Milford, MA) and dried down. The peptides were resuspended in TEAB prior to high pH reversed-phase chromatography. The 60 fractions obtained were combined in 15 final fractions using a concatenation strategy, prior desalting using OMIX C18 tips (Varian, Inc., Palo Alto, CA). After elution, the peptides were dried-down and analyzed by reverse phase-high performance liquid chromatography (RP-HPLC)-Q-OT-qIT analysis.

All digested samples were analyzed by liquid-chromatography-tandem MS (LC-MS/MS) using an EASY-nLC 1000 system coupled to an Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA). Peptides were on-line eluted on an analytical RP column (0.075 × 250 mm Acclaim PepMap RLSC nano Viper, Thermo Fisher Scientific), operating at 300 nL/min using the following gradient: 5--25% B for 40 min, 25--44% B for 20 min, 44--80% B in 10 s, 80% B for 5 min, 80--5% in 10 s, and 5% B for 20 min \[solvent A: 0.1% formic acid (v/v); solvent B: 0.1% formic acid (v/v), 80% CH~3~CN (v/v) (Fisher Scientific, Pittsburgh, PA)\]. The Orbitrap Fusion was operated in a data-dependent MS/MS mode using the 10 most intense precursors detected in a survey scan from 380 to 1,400 m/z performed at 120K resolution. Tandem MS was performed by HCD fragmentation with normalized collision energy (NCE) of 30.0%.

Protein identification was carried out using ProLuCID algorithm([@bib60]) (Integrated Proteomics Pipeline v.3, Integrated Proteomics Applications INC., San Diego, CA), allowing optional modifications (Met oxidation, Asn/Gln deamidation), two missed cleavages, and mass tolerance of 10 and 20 ppm for precursor and fragment ions, respectively. MS/MS raw files were searched against a homemade database containing the sequence of the complete Mouse proteome, human keratins and porcine trypsin. The raw files were also searched against a reverse sequences database. The false discovery rates (FDR) of peptide identifications were calculated to be 4.36 and 1.59 at the protein and peptide level respectively.

Stress models {#s4-8}
-------------

Male mice, age 2--3 months old were used in all stress related experiments, All animals were age and weight matched before commencement of any stress paradigm and were randomly assigned into the stress group or non-stress group.

Unpredictable chronic mild stress paradigm: For the unpredictable chronic mild stress (UCMS) paradigm, mice were housed in individual cages and allowed 1 week to habituate before beginning experimentation after which mice were subjected to 4 weeks of stressors with two stressors applied within a 24 hr period. Stressors were applied pseudo-randomly and included intermittent bell (10 db, 1/10 s), continuous white noise (4 hr), rat odor, cage tilt (45°, 4 hr), cage shaking (30 min), soiled bedding (8 hr), paired housing (with new partner, 2 hr), overnight illumination, removal of nesting material (12 hr), placement of novel object in home cage (3 hr) and confinement in a small cage (80 cm^3^, 1 hr). Stressors continued to be applied during the behavioral testing phase. No stressors were applied on the day of testing (18 hr prior to any behavioral testing) to avoid effects of fatigue and acute stress. Non-stressed mice were left undisturbed in their home cages. Biochemical analysis was performed using the mPFC of mice isolated 1 hr following the final exposure to UCSM. The diagram below summarizes the time course outlining when the behavioral tests were performed with respect to chronic stress:

![Timeline for behavioral evaluation in stress-induced depression models.](elife-33273-fig9){#C1}

Physical restraint stress paradigm: Physical restraint stress (PRS) was performed in plastic tube (30 mm diameter x 115 mm length) with holes for ventilation. Mice were restrained horizontally in tubes for 2 hr for 14 days. Non-stressed mice were left undisturbed in their home cages. During behavioral testing, mice were not subjected to PRS to avoid effects of fatigue and acute stress. Biochemical analysis was performed using the mPFC of mice isolated 1 hr following the final exposure to PRS.

Corticosterone paradigm: For the corticosterone study, pure corticosterone (Sigma-Aldridge, St. Louis, MO) was dissolved in 50% propylene glycol. Mice were administered corticosterone (20 mg/kg, s.c.) or vehicle for 14 days. Biochemical analysis was performed using the mPFC of mice following 1 hr post-injection time.

Stress-induced hypothermia: Mice undergoing stress-induced hypothermia (SIH) were housed singly overnight in the testing room with free access to food and water. Rectal temperature was measured twice in each mouse at *t* = 0 (T1) and *t* = 15 min (T2), where the difference between the temperatures (T2-T1) is considered the SIH score. Temperature was measured when a stable recording was observed, approximately 15 s following the insertion of the probe (ThermoWorks, American Fork, UT).

Drug treatments {#s4-9}
---------------

Mice were injected with saline on three consecutive days before the start of the study to acclimate the animals to the injection procedure. RU-486 (Sigma-Aldridge, St. Louis, MO) was injected at dose of 10 mg/kg for three consecutive days ([@bib62]) and tissue was isolated 30 min post-injection time. NBQX (Tocris Bristol, United Kingdom) was administered at a single dose of 10 mg/kg (i.p.) or appropriate vehicle and 30 min later were subjected to the behavioral testing.

Recombinant helper dependent adenoviral production of GPR158 over-expression vector {#s4-10}
-----------------------------------------------------------------------------------

GPR158 was first cloned into the high-level neuronal transgene expression cassette pUNISHER ([@bib35]) for rapid and long term in vivo neuronal expression in the CNS. Briefly, this cassette includes the 365 bp human cytomegalovirus enhancer; 470 bp human *synapsin* promoter, the 107 bp 5' amyloid precursor protein untranslated region, the 92 bp minute virus of mice intron, 592 bp woodchuck posttranscriptional regulatory element, the 241 bp tau 3' UTR and the 224 bp bovine growth hormone polyadenylation signal. Subsequently, the expression cassette was cloned into the AscI site of pdelta 28E4, gift from Dr. Phil Ng ([@bib41]) using In Fusion, Clontech. This version of pdelta28E4 has been modified to contain 21 kbp of stuffer DNA and a separate neurospecific EGFP expression cassette that is driven by the hsyn promoter. The final HdAd plasmid allows for over-expression of GPR158 independently of EGFP as a dual expression recombinant Ad vector similar to the strategy used with 2^nd^ generation rAd vectors which lead to no toxicity in neurons ([@bib9]; [@bib35]). Production of HdAd was carried out as previously described ([@bib42]). Briefly, HdAds were produced by first digesting the pHdAd with PmeI to linearize and expose the ends of the 5' and 3' ITRs. Transfection of the pHdAd was performed using 116 producer cells, a modified HEK293 line expressing high levels of the Cre recombinase enzyme, and a 4-kbp adenoviral genome fragment that encodes for the E1A/E1B gene, necessary for rAd to replicate ([@bib41]). The standard protocols for recombinant Helper-Dependent Adenovirus production were followed ([@bib42]) with slight modifications ([@bib36]). HdAd was serially amplified in five consecutive passages from 3 60 mm tissue culture dishes followed by one 15 cm dish and finally 30 15 cm dishes. Each successive passage was performed after cytopathic effect (CPE) occurred and cell lysates were subjected to three freeze/thaw cycles to lyse cells and thereby release the viral particles. HdAd was stored at −80°C in storage buffer (in mM): 10 HEPES, 250 sucrose, 1 MgCl~2~ at pH 7.4 ([@bib13]). Viral particle/mL was calculated ([@bib42]) as follows:

Viral particles/ml = (A260) x (dilution factor) x (1.1 × 10^12^) x (36)/ (size of the vector in kb)

Viral Titer: HdAd 23E4 Pun GPR158 syn EGFP 7.11 × 10^12^ vp/ml

Behavioral measures {#s4-11}
-------------------

All behavioral experiments were carried out with the experimenter blind to genotype and/or treatment history.

### Marble Burying {#s4-11-1}

Marble burying (MB) was conducted in a homecage-like environment (27 × 16.5 × 12.5 cm) with 5 cm corncob bedding and 20 glass marbles overlaid in a 4 × 5 equidistant arrangement. Background white noise (approximately 70 dB) was used during trials. The mouse was placed in the corner of the cage and testing consisted of a 30 min exploration period. The number of marbles that were at least two-thirds buried at the end of the trial were counted as buried.

### Elevated Plus Maze {#s4-11-2}

The elevated plus maze was performed using a black, plexiglass elevated plus maze (apparatus with two open and two enclosed arms 33 × 6 cm with a wall of 25 cm on the closed arm, elevated 60 cm from the floor; Med Associates, St. Albans, VT). Lighting for the maze was set at 200 lux in the center of the plus maze, 270 lux on the open arms, and 120 lux on the closed arms. Background white noise (approximately 70 dB) was used during trials. Mice were placed in the center of the elevated plus maze and left to explore for 5 min in dim light condition. Mice were recorded using Ethovision XT and the time spent in the open and closed arms and the number of entries from the closed to the open arm was calculated.

### Force Swim Test {#s4-11-3}

The Porsolt FST was conducted using vertical clear glass cylinder (10 cm in diameter, 25 cm in height) filled with water (25°C). The mice spent 6 min in the water and immobility was scored from 2 to 6 min. A mouse was regarded as immobile when floating motionless or making only those movements necessary to keep its head above the water.

### Tail suspension test {#s4-11-4}

The tails of the mice were wrapped with tape that covered approximately 4/5 of the tail length and then fixed upside down on a hook. The immobility time of each mouse was recorded and tracked over a 6 min period using Ethovision XT.

### 2-bottle Sucrose test {#s4-11-5}

Mice undergoing the sucrose preference test were habituated to 1% sucrose solution or water for 4 days and the bottle position was counterbalanced across days. Mice were individually housed in cages during the testing phase. On testing day, mice were water-deprived (12 hr) and then presented with pre-weighed identical bottles of water and 1% sucrose solution for 12 hr. The sucrose preference was calculated by dividing the volume of sucrose solution consumed by the total volume of liquid consumed.

### Rotarod {#s4-11-6}

Motor coordination was assessed using an accelerating rotarod apparatus (IITC Life Science, Woodland Hills, CA). The apparatus consists of a rod covered in rubber that is approximately 30 mm in diameter and is approximately15cm above the floor of the bay. Mice performed 3 trials over 2 days. Mice were placed on a rod that accelerated from 4 to 27 rpm over 5 min and the time to fall to the floor of the apparatus, or to turn around one full revolution while hanging onto the drum was measured.

### Locomotor activity {#s4-11-7}

Locomotor activity was performed in 40 × 40×35 cm chambers (Stoelting Co, Wood Dale, IL) and distance traveled was recorded for 2 hr using Anymaze video-tracking software and analyzed in 10 min bins.

Analysis of emotionality score {#s4-12}
------------------------------

The behavioral paradigm used to calculate the emotionality score were performed in the following order with 3--4 days between testing to minimize the effects of the previous test: MB, EPM, TST and FST. To obtain a comprehensive measure for emotionality, we used z-scoring methodology to integrate standard measures of anxiety-like and depressive-like behaviors, as previously described ([@bib16]; [@bib23]; [@bib30]). The testing parameters analyzed were as follows: marble burying (number of marble buried), elevated plus maze (time spent on open arm, number of entries into the open arm), tail suspension test (immobility) and forced swim test (immobility). For each parameter, the z-score for every individual animal was calculated using the following formula:$$Z\  = \frac{X - \mu}{\sigma}$$where X represents the individual data point, μ represents the mean of control group and σ represents the standard deviation of the control group. The emotionality score for each individual subject was first averaged within test, and then across each test to ensure equal weighting of all tests.$$\text{Emotionality\ score=}\frac{Z_{\text{MB}} + Z_{\text{EPM}}\  + \ Z_{\text{TST}}\  + \ Z_{\text{FST}}\ }{number\ of\ tests}$$

The mean emotionality score for each group is an average of the individual within each group for each experiment.

cAMP measurements {#s4-13}
-----------------

Prefrontal cortex tissue punches (2 mm) were flash frozen in liquid nitrogen before homogenization in 20 mM HEPES pH 8.0, 1 mM EDTA, 150 mM NaCl, 2 mM MgCl2, 1 mM DTT, and cOmplete protease inhibitor (Roche, Indianapolis, IN) followed by centrifugation at 2000 x g to clear nuclear debris. Total cAMP was determined by diluting supernatant 1:50 in 0.1 N HCl followed by quantification using a competitive cAMP enzyme immunoassay according to the manufacturer's guidelines (Direct cAMP ELISA kit, ENZO Life Sciences, Farmingdale, NY).

Monoamine levels {#s4-14}
----------------

Norepinephrine (NE), 3-methoxy-4-hydroxyphenylglycol (MHPG), 3,4-dihydroxyphenylacetyic acid (DOPAC), dopamine (DA), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) and serotonin (5-HT) in brain samples were analyzed using high performance liquid chromatography with electrochemical detection. The medial prefrontal cortex was microdissected from 200 µm coronal sections using a 300 µm punch under a dissecting microscope equipped with a freezing stage (Physitemp Instruments Inc., Clifton, NJ). The microdissected tissue was expelled into 60 µL of sodium acetate buffer (pH 5.0) containing the internal standard alpha-methyl dopamine (Merck and Co., Inc., Kenilworth, NJ) and stored at −70^o^ C. Prior to analysis, the samples were thawed and 3 μL ascorbate oxidase (1 mg/mL, Sigma-Aldridge, St. Louis, MO) was added to each sample followed by centrifugation at 17,000 $\times$ g for 10 min. The supernatant (60 µL) was removed from the samples and a Waters Alliance e2695 separations module was used to inject 50 µL of the supernatant onto a C~18~4 µm NOVA-PAK radial compression column (Waters Associates, Inc. Milford, MA). The initial mobile phase (pH 4.1) was prepared using 8.6 g sodium acetate, 250 mg EDTA, 14 g citric acid, 80 mg octylsulfonic acid, and 80 mL methanol in 1 L of distilled water (monoamine standards and chemicals were purchased through Sigma-Aldridge, St. Louis, MO) and adjusted with small additions of octylsulfonic acid, glacial acetic acid and methanol to optimize the separation. Electrochemical detection of amines was accomplished using an LC four potentiostat and glassy carbon electrode (Bioanalytical Systems, West Lafayette, IN) set at a sensitivity of 0.5 nA/V with an applied potential of +0.87 V versus an Ag/AgCl reference electrode. The pellet was solubilized in 200 µL of 0.4 N NaOH and protein content was analyzed using the Bradford method. A CSW32 data program (DataApex Ltd., Czech Republic) was used to determine monoamine concentrations in the internal standard mode using peak heights calculated from standards. Corrections were made for injection versus preparation volumes and monoamine concentrations were normalized by dividing pg monoamine by µg protein in the sample.

Spine density analysis {#s4-15}
----------------------

Coronal sections (300 µm) were obtained in the region located between 2.10 mm and 1.54 mm rostral to the bregma. Pyramidal neurons of the layer 2/3 in the prelimbic region of the medial prefrontal cortex were injected with biocytin. Streptavidin-conjugated HRP was used to label the injected neurons using a green fluorescent substrate. Each section was then mounted on a slide and confocal images were obtained using at The Light Microscopy Facility, the Max Planck Florida Institute, using a confocal microscope (LSM 780; Carl Zeiss; Plan Apochromat 40x/1.3 Oil DIC M27) at room temperature. Image acquisition and processing were accomplished using ZEN 2011 (64 bit) software (Carl Zeiss, Oberkochen, Germany) with only minor manipulations of the images setting the fluorescence intensity in non-saturating conditions and maintaining similar parameters for each acquired image. Pictures were elaborated and spine density calculated using ImageJ and Neurolucida (MicroBrightField, Williston, VT) software. Only apical dendrites of second order were analyzed. At least three segments/neuron (\>40 µm; average of 420 µm/mouse) with similar diameter (average of 1.06 ± 0.21 µm) that did not show intersections with other dendrites were considered for analysis. All measurements were performed by an experimenter blind to the mice genotype.

Whole-cell patch clamp recordings {#s4-16}
---------------------------------

Coronal slices (300 µm) containing prefrontal cortex (AP +1.7--1.9) were cut in ice-cold aCSF (in mM: 124 NaCl, 2.8 KCl, 1.25 NaH~2~PO~4~, 2 CaCl~2~, 1.25 MgSO~4~, 26 NaHCO~3~, 10 glucose, pH 7.5, bubbled with 95% O~2~/5% CO~2~) using a vibrating tissue slicer (VT1200, Leica). The slices were placed into individual wells of a custom slice incubation chamber where they remained in oxygenated aCSF at 32--36°C until use. During recording, PFC slices were transferred to a submerged recording chamber where they were continuously perfused with oxygenated aCSF with picrotoxin (100 µM), and maintained at 32--36°C. Voltage-clamp whole-cell recordings were obtained with borosilicate glass pipettes (2--5 MΩ) filled with the following solution (in mM): 115 CsMeSO~3~, 10 CsCl, 5 NaCl, 10 HEPES, 0.6 EGTA, 20 TEA, 4 MgATP, 0.3 Na~2~GTP, 5 QX314, with a pH of 7.35 and osmolarity of 310 mOsmol. Data were collected from neurons with resting membrane potential (RMP) more negative than −60 mV and initial series resistance ≤20 MΩ. Cells with series resistance changed more than 25% during recording period were excluded from analysis. Spontaneous excitatory postsynaptic currents (sEPSCs) were recorded at -- 70 mV. Evoked EPSCs were recorded using a bipolar stimulating electrode located \~100 µm away from the neurons. AMPAR- and NMDAR-mediated components were identified according to their distinct activation mechanisms and deactivation kinetics ([@bib10]; [@bib38]). AMPAR mediated EPSCs were recorded at -- 70 mV and measured as the peak response following the stimulus. NMDAR mediated EPSCs were recorded at +40 mV and measured as the mean current over a 5 ms window, 50 ms after the stimulus. Mean EPSCs were an average of 10--15 sweeps obtained at 0.1 Hz. For paired-pulse ratio (PPR) recordings, a paired-pulse protocol of two stimuli at an inter pulse interval of 50 ms was applied while the cells were voltage-clamped at -- 70 mV. Paired-pulse ratio was defined as the second peak amplitude (P2) divided by the first peak amplitude (P1). Mean PPRs were an average of 5--10 sweeps acquired at 1/15 Hz. Synaptic responses were collected with a HEKA EPC10 amplifier system (HEKA Instruments, Holliston, MA). Data were transferred to a PC computer using an ITC-16 digital-to-analog converter (HEKA Instruments). The signals were filtered at 2.9 kHz and digitized at 10 kHz using Patchmaster software (HEKA Instruments). Data were analyzed offline using Patchmaster. Voltages were not corrected for the liquid-liquid junction potential.

Preparation of acute cortical slices {#s4-17}
------------------------------------

Acute coronal cortical slices containing medial prefrontal cortex (mPFC) were prepared from C57BL/6 wild type and *Gpr158^-/-^* mice, P50-60. Mice were anesthetized with isoflurane and decapitated. The brain was removed from the skull and rapidly placed in ice-cold cutting solution containing (in mM): 215 sucrose, 20 glucose, 26 NaHCO~3~, 4 MgCl~2~, 4 MgSO~4~, 1.6 NaH~2~PO~4~, 1 CaCl~2~ and 2.5 KCl. Cortical slices (400 μm thick) were prepared using a VT1000S vibrating microtome (Leica). Slices were incubated at 32°C for 30 min in a holding chamber containing 50% cutting solution and 50% artificial cerebrospinal fluid (ACSF; in mM: 127 NaCl, 25 NaHCO~3~, 1.25 NaH~2~PO~4~, 2.5 KCl, 25 D-glucose, 2 CaCl~2~, and 1 MgCl~2~). After 30 min, this solution was replaced with ACSF at room temperature. Slices were allowed to recover for more than 1 hr in ACSF before recording. All solutions were equilibrated for at least 30 min with 95%O~2~/5%CO~2~.

Two-photon imaging, electrophysiology, and glutamate uncaging {#s4-18}
-------------------------------------------------------------

Layer 2/3 pyramidal neurons of prelimbic (PrL) subregion in the mPFC at depths of 20--40 μm were imaged using a two-photon microscope (Prairie Technologies, Inc) with a pulsed Ti::sapphire laser (MaiTai HP DeepSee, Spectra Physics) tuned to 920 nm (2--2.5 mW at the sample) in recirculating ACSF aerated with 95%O~2~/5%CO~2~ containing (in mM): 2 Ca^2+^, 1 Mg^2+^, 0.001 TTX, and 2.5 MNI-caged-glutamate. For each neuron, image stacks (512 × 512 pixels; 0.035 µm / pixel) with 1 μm z-steps were collected from one segment of secondary or tertiary apical and/or basal dendrites 30--80 μm from the soma. All images shown are maximum projections of 3D image stacks after applying a median filter (2 × 2) to the raw image data. Whole-cell recordings (electrode resistances 5--8 MΩ; series resistances 20--40 MΩ) were performed at 25°C on visually identified PrL layer 2/3 pyramidal neurons within 40 μm of the slice surface using a MultiClamp 700B amplifier (Molecular Devices, Sunnyvale, CA). In brief, to record uncaging-evoked excitatory postsynaptic currents (uEPSCs), PrL neurons were patched in voltage-clamp configuration (Vhold = −65 mV and +40 mV for AMPA receptor- and NMDA receptor-mediated uEPSCs, respectively) using cesium-based internal solution (in mM: 135 Cs-methanesulfonate, 10 HEPES, 10 Na2 phosphocreatine, 4 MgCl2, 4 Na2-ATP, 0.4 Na-GTP, 3 Na L-ascorbate, 0.2 Alexa 488,\~300 mOsm, \~pH 7.25) in ACSF. uEPSC amplitudes from individual spines were quantified as the average (8--10 test pulses of 1 ms duration at 0.1 Hz) from a 2 ms window centered on the maximum current amplitude after uncaging pulse delivery for AMPA currents and from a 10 ms window between 70 and 80 ms after stimulus for NMDA currents. Laser pulses were delivered by parking the beam at a point ∼0.5 μm from the center of the spine head with a pulsed Ti::sapphire laser (MaiTai HP, Spectra-Physics) tuned to 720 nm (16--18 mW at the sample). Integrated green (Alexa 488) fluorescence intensities were measured from background-subtracted green fluorescence using the integrated pixel intensity of a boxed region surrounding the spine head. Estimated spine size was calculated by normalizing the fluorescence intensities (as described above) for each individual spine to the mean fluorescence intensities measured from four ROIs on the dendritic shaft.

Human subjects {#s4-19}
--------------

Post-mortem tissues were obtained from the NIH NeuroBioBank at the University of Pittsburg, University of Miami Brain Endowment Bank and the Human Brain and Spinal Fluid Resource Center (Los Angeles). Informed consent was obtained from the next of kin for all subjects, and all procedures were approved by each institutions' internal review board; University of Pittsburgh Institutional Review Board for Biomedical Research, University of Miami Institutional Review Board and the Institutional Review Board for the Department of Veterans Affairs. Tissue from the dorsolateral prefrontal cortex from nine individuals that met the DMS-IV criteria for MDD and eight control individuals with no history of neurological or psychiatric illnesses were procured.

Quantification and statistical analysis {#s4-20}
---------------------------------------

Statistical analysis was performed using GraphPad Prism (Prism6.0, GraphPad, San Diego, California). Student's *t*-test was used to compare means between two groups, and one-way or two-way analysis of variance followed by Tukey's or Bonferroni *post hoc* tests were used to determine significant differences among multiple groups. Frequency distributions were compared using the Kolmogorov--Smirnov test. Statistical tests were performed two-sided unless stated otherwise. Differences were considered significant if p\<0.05. All data are expressed as means ± s.e.m. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally employed in comparable studies.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Orphan receptor GPR158 controls stress-induced depression\" for consideration by *eLife*. Your article has been favorably evaluated by a Senior Editor and three reviewers, one of whom is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal his identity: Thomas L. Kash (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this letter to help you prepare a revised manuscript.

This paper proposes that the abundance of an orphan G-protein coupled receptor (Gpr158) in the pre-frontal cortex (PFC) increases with stress (or glucocorticoid treatment) and that promotes depression-like behaviors of mice. Deliberate overexpression of GPR158 (by viral transduction) in PFC promotes depression-like behaviors and knockout of Gpr158 gene (everywhere) has anti-depression effects.

All three reviewers agree that this is an intriguing study that begins to assign a function to Gpr158; however, there are some major concerns that need to be addressed prior to publication.

Major points:

1\) It is important to delineate the functions of Gpr158 in specific populations of PFC neurons because the functions in glutamatergic and GABAergic neurons may differ. Without that information, overexpression of Gpr158 in all PFC neurons is difficult to interpret.

2\) Of the many GABAergic neurons, is Gpr158 expression restricted to the parvalbumin-expressing neurons?

3\) The signaling pathways engaged in glutamatergic and GABAergic neurons should be established, at least to the level of knowing whether it is excitatory or inhibitory.

4\) Because Gpr158 is expressed widely in the brain, the effect of knockout or knockdown of Gpr158 in the PFC (ideally in pyramidal or glia cells) on behavior is needed.

5\) The authors should discuss the possibility that osteocalcin is an endogenous ligand for Gpr158 and what significance that has for interpretation of their results.

6\) The authors should validate the antibody used in their studies more thoroughly and describe the genetic background and breeding strategy.

*Reviewer \#1:*

The GPR158-Ad virus presumably infects all cells in the PFC, including those that do not normally express this GPCR. Thus, it is not possible to conclude that upregulation of GPR158 in cells where it is normally expressed promotes depression-like behaviors, it only shows that this ectopic expression paradigm seems to work. There is no evidence that the PFC is a specific region where GPR158 can affect depression-like behaviors-perhaps increasing GPR158 levels in other brain regions is also effective.

The observation that GPR158 is in both excitatory pyramidal neurons and GABAergic PV neurons in the PFC raises the question of whether this GPCR signaling is more important and whether the signaling mechanism is the same in both cell types.

The behavioral studies with GPR158 KO and WT mice are nice, but they do not bear on the brain region where this orphan receptor is important. Restoring GPR158 in neurons that normally make it in the PFC on a KO background and performing the behavioral and electrophysiological experiments would go a long way towards solidifying this story.

The genetic background of the GPR158 WT and KO mice used here should be indicated. Were the WT and KO mice used for these studies littermates derived from breeding heterozygotes? If not, there is concern that WT and KO mice used for studies may have subtle genetic background differences.

A recent study suggests that GPR158 is activated by osteocalcin (J Exp Med 214, 2859), that it participates in hippocampal memory and that it is coupled to G-α-q signaling. The results in this study do not seem to be compatible with G-α-q signaling.

*Reviewer \#2:*

This is a novel finding, identifying GPR158 as an important mediator of stress induced depression like behavior. The authors test this idea by over expressing and knocking out this receptor and assessing behavior. In addition, the authors provide data showing changes of this GPCR in human MDD patient brain. This is a nice addition that lends cross species generalizability. However, some of the experiments are concerning:

1\) Over-expression is not directed to any cell type, so while the behavioral data is robust, it is challenging to interpret. Of additional concern, this is only explored in male mice. given later data in the KO mice was examined in males and female mice, seem like a useful comparison.

2\) The knockout data is compelling in such that deletion from birth can induce changes in behavior, synaptic function independent of stress exposure. This raises the issue that there could be a developmental compensation from the deletion of the receptor.

Because of these issues, I think a more robust analysis would be a viral knockdown of GPR158 prior to stress exposure to parse out role of developmental deletion. These issues are not addressed in the manuscript, and given the novelty of these findings and the potential length of time it would take to repeat these experiments with a knockdown approach, I would also be favorable if there were a more in depth discussion of these concerns in the manuscript.

3\) The authors present data showing that layer 2/3 neurons in the mPFC are altered. Given the expression of this protein in nearly all GABA neurons, this is an incomplete analysis. These particular experiments, recording from different cell types in KO and WT mice, would be very helpful in clarifying molecular/synaptic adaptations.

4\) The near total exclusion of this GPCR in SST neurons is stunning. It is a bit confusing how the expression in GABA neurons is so high, but nothing in SST. It would be useful to flush this out a bit more with triple labeling, to provide further evidence of this selective expression.

*Reviewer \#3:*

This is a very interesting manuscript from Martemyanov and colleagues showing that expression of the orphan GPCR GPR158 is glucocorticoid-regulated, is highly expressed in rodent prefrontal cortex, and is upregulated in post-mortem dlPFC from depressed human patients and in rodents subjected to behavioral procedures that precipitate depression-like behavioral responses. Furthermore, virus-mediated GPR158 overexpression in PFC precipitates depression-like behaviors in rodents and that knockout mice show the opposite.

Overall, this is a rigorously-performed and well-written study that is likely to be of considerable interest to the field, particularly those interested in new medications development.

I have only a few comments for the authors\' consideration:

1\) It is important to validate the antibody used for immunofluorescence work in the KO mice. If it is selective, then the signal should not be detected in the PFC (or elsewhere) in the KO mice. It is understood that bands were not detected in KO tissues when using this antibody for immunoblotting. But, frequently antibodies that are relatively selective when used for immunoblotting will bind nonspecifically when used for immunoimaging.

2\) It appears from the presented immunoimaging that GPR158 is not cortically-enriched but rather expressed in most brain regions captured in the representative brain slice that is shown, with the exception of the white matter tracts as expected. This begs the question of whether GPR158 is active in other brain regions and if similar effects as those reported for the PFC in mice would have been detected when GPR158 expression is manipulated in other brain regions implicated in the regulation of depression-related behaviors, such as the hippocampus, accumbens etc. In other words, there are no anatomical controls in the current data-set to confirm that reported effects are anatomically selective. This is not a major issue, as the reported data are compelling, but some data related to other brain sites would have further strengthened the manuscript.

3\) Greater consideration should be given to the endogenous agonist for GPR158, and more broadly the likely signaling mechanisms for the receptor should be presented in the manuscript. I am not suggesting that the authors seek to de-orphanize the receptor as this is beyond the scope of this manuscript. However, is there any evidence from the published literature that hints at the identity of the endogenous agonist? Is GPR158 directly activated by glucocorticoids? To which intracellular signaling complex does GPR158 couple?

10.7554/eLife.33273.021

Author response

> Major points:
>
> 1\) It is important to delineate the functions of Gpr158 in specific populations of PFC neurons because the functions in glutamatergic and GABAergic neurons may differ. Without that information, overexpression of Gpr158 in all PFC neurons is difficult to interpret.

The current manuscript deals primarily with the role of Gpr158 in glutamatergic pyramidal neurons in the PFC. The following lines of evidence that we present indicates that Gpr158 significantly impacts their function. 1) morphological changes induced by Gpr158 loss occur in glutamatergic neurons ([Figure 7A](#fig7){ref-type="fig"}); 2) changes in synaptic strength and AMPA receptor function upon ablation of Gpr158 also happen in glutamatergic neurons ([Figure 7B-I](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1B-C](#fig7s1){ref-type="fig"}). The identity of neurons examined in these datasets may not have been made sufficiently clear and we clarified this upon revision. Additionally, we solidify the role of Gpr158 in glutamatergic neurons by supplying the following new data in the revised manuscript. 3) We showed that stress specifically regulates Gpr158 levels only in glutamatergic and not GABAergic neurons ([Figure 2A-C](#fig2){ref-type="fig"}). In these experiments we subjected mice to stress and examined cell-specificity of Gpr158 modulation. Because Gpr158 plays a role in controlling depressive--like phenotypes that we document by both gain and loss of function studies and because these changes are precipitated by stress we think that these data serve as an additional evidence for the role of Gpr158 in glutamatergic neurons in controlling behavioral outcomes. 4) We additionally report changes in processing neurotransmitter inputs onto glutamatergic neurons obtained by patch clamping glutamatergic neurons specifically and recording their sEPSC ([Figure 7B-D](#fig7){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). The modulation of sEPSC frequency that we observe in this population further argues for the involvement of Gpr158 in controlling the signal processing by glutamatergic neurons. We feel that together this dataset provides compelling evidence pointing to Gpr158 action in glutamatergic neurons.

> 2\) Of the many GABAergic neurons, is Gpr158 expression restricted to the parvalbumin-expressing neurons?

The format and quantification that we used in the original manuscript may have been unclear and did not directly support the intent of examining the cell specificity of Gpr158 expression. In our study we used latest generation of in situ hybridization technique that provides cellular resolution of mRNA expression to define the expression of Gpr158 in the cellular populations of the PFC based on double labeling with known cellular markers. In accordance with the published literature we detect that \~70% in the region are glutamatergic, \~11% are GABAergic and \~19% are glia. The expression of Gpr158 is detected in all glutamatergic neurons and none in glia. We also detect Gpr158 expression in most GABAergic neurons. However, given their diversity, the attribution to specific subtypes is not as straightforward due to overlapping marker expression, lack of the specific subtype markers for many Gpr158-expressing cells and limitation of the in situ technique that only allows dual labeling. On re-examination of the data we came to the conclusion that we cannot confidently determine the identity of the SST+ cells that do not express Gpr158. In the revised manuscript we simplified the analysis to avoid possible confusion and misattribution by focusing on Gpr158 expressing cells and defining what markers they express. This analysis is straightforward and shows that 90% of Gpr158 positive cells are glutamatergic neurons, 10% are Gad1 positive, 1.5% are parvalbumin positive and none of the \~750 cells examined in each double in situ hybridization experiment show co-expression with glial markers or somatostatin ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). We feel that because the current study emphasized the role of Gpr158 in glutamatergic neurons and does not study the effects in GABAergic population, subdivision of their expression in GABAergic neurons may be not essential but rather detracting from the main points of the paper, hence these claims were de-emphasized.

> 3\) The signaling pathways engaged in glutamatergic and GABAergic neurons should be established, at least to the level of knowing whether it is excitatory or inhibitory.

In the revised manuscript we provide the results of systematic analysis of signaling pathways engaged by Gpr158 ([Figure 8](#fig8){ref-type="fig"}). We performed a screen looking at a variety of signaling molecules impacted by Gpr158 ablation in the PFC ([Figure 8A-B](#fig8){ref-type="fig"}). Most notably this includes the discovery that Gpr158 loss significantly upregulates neurotrophic factor BDNF and that this effect is mediated by changes in eEF2 phosphorylation which regulates local translation rather than affected by transcriptional upregulation ([Figure 8C-E](#fig8){ref-type="fig"}). Identification of BDNF as a signaling mediator of Gpr158 effects is exciting because it further mechanistically links signaling changes to observed changes in neuronal morphology as well as antidepressant effects that alter AMPA/NMDAR function, such as ketamine. Given consistent increase in virtually all measures reporting increase in neuronal activity: synaptic strength, sEPSC), spine number, cAMP, AMPA receptor currents and BDNF expression observed upon Gpr158 loss, we think this data strongly suggests that Gpr158 is an inhibitory receptor. This point is addressed in the revised manuscript.

> 4\) Because Gpr158 is expressed widely in the brain, the effect of knockout or knockdown of Gpr158 in the PFC (ideally in pyramidal or glia cells) on behavior is needed.

The main emphasis of this paper is on molecular mediators that control stress induced changes in depression. We identified that stress upregulates Gpr158 levels specifically in the PFC. To further reinforce regional specificity of this effect we added results examining modulation of Gpr158 levels across different brain regions involved in depressive like behaviors (Cerebellum, Caudate/Putamen, Nucleus Accumbens and Hippocampus) that shows exclusive modulation of Gpr158 in the PFC prompting us to focus current study on this region ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). The viral overexpression of Gpr158 in the PFC and the rescue of Gpr158 specifically in the PFC of knockout mice provides sufficient evidence supporting the contribution of Gpr158 in this region to stress mediated depression. Given that we report that Gpr158 upregulates AMPA receptor function in the PFC, we solidify our evidence by demonstrating that partial blockade of AMPA receptor function by subthreshold doses on NBQX administration reverses the antidepressant-like effects in Gpr158 knockout mice ([Figure 7J](#fig7){ref-type="fig"}). Lastly, given the lack of Gpr158 expression in glia, the neuronal specific tropism of Ad virus with synaptophysin promoter that we used for the expression of Gpr158 in the PFC, we do not think that glial specific knockdown or rescue experiments are warranted. Similarly, as discussed above, the lack of Gpr158 regulation by stress in GABAergic neurons makes knockdown or rescue of this protein specifically in this population tangential to the main emphasis and conclusions of this study.

We would also like to note that although we show changes in PFC to be sufficient in explaining Gpr158 behavioral effects (viral overexpression/knockout in the PFC) we cannot formally exclude possible role that Gpr158 also plays in other regions in contributing to anti-depressant behaviors (unrelated to stress), which in no way invalidates our findings in the PFC. Collectively, we are able to conclude that Gpr158 in the glutamatergic neurons in the mPFC is sufficient to drive stress-induced changes in the behavior. This will not completely exclude the role Gpr158 has in GABAergic neurons but we believe this line of research is beyond of the scope of this paper.

> 5\) The authors should discuss the possibility that osteocalcin is an endogenous ligand for Gpr158 and what significance that has for interpretation of their results.

We have addressed this in the Discussion section of the revised manuscript. The rapid progress in understanding GPR158 functions in the brain is exciting. We would like to note that the osteocalcin report was published while this manuscript was already in the peer review process. We are certainly happy to discuss this new development, however, we feel that extending our report along these lines experimentally may better be suited for future studies. Comparing our results in PFC with the data reported in the hippocampus reveals that there may be major significant differences in GPR158 signaling properties between neurons of PFC and hippocampus. While this is not entirely unusual for a GPCR to exhibit region selective signaling bias, determining the exact mechanisms and possible presence of additional endogenous ligands is outside of the scope of the current report, which is already quite extensive.

> 6\) The authors should validate the antibody used in their studies more thoroughly and describe the genetic background and breeding strategy.

The antibodies used were for Western blotting and have been thoroughly validated using KO tissues. The results showed the complete lack of the band that we consider to be Gpr158, thus confirming the specificity for this application. We did not use these antibodies for the immunohistochemistry because they produce diffuse neuropilar staining pattern (although specific), which does not allow easy attribution of cell specificity. Therefore, instead we have used the latest generation fluorescent in situ hybridization that provides sensitive detection of mRNA expression with high specificity and cellular resolution. We may not have been sufficiently clear as to what technique we have used to characterize Gpr158 expression and we have since clarified this in the revised manuscript. In addition, we have included control that established specificity of in situ hybridization reactions ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}).

In terms of the genetic background -- the mice were generated on a pure C57BL6 background and have been maintained as heterozygous breeding pairs producing -/- and +/+ littermates used of all of the studies in the paper. We relied exclusively on littermates for all the comparisons. Again, we will clarify this in the revised manuscript.

> Reviewer \#1:
>
> The GPR158-Ad virus presumably infects all cells in the PFC, including those that do not normally express this GPCR. Thus, it is not possible to conclude that upregulation of GPR158 in cells where it is normally expressed promotes depression-like behaviors, it only shows that this ectopic expression paradigm seems to work. There is no evidence that the PFC is a specific region where GPR158 can affect depression-like behaviors-perhaps increasing GPR158 levels in other brain regions is also effective.

To address regional specificity we have analyzed Gpr158 protein levels following stress in other brain regions including nucleus accumbens and hippocampus ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). However, we have only observed the upregulation of Gpr158 in the mPFC following chronic-stress exposure. While we cannot rule out the importance of Gpr158 in other brain regions, we can conclude that Gpr158 in the mPFC is sufficient to drive stress-mediated responses. We have also addressed this concept of regional specificity in the Discussion.

> The observation that GPR158 is in both excitatory pyramidal neurons and GABAergic PV neurons in the PFC raises the question of whether this GPCR signaling is more important and whether the signaling mechanism is the same in both cell types.
>
> The behavioral studies with GPR158 KO and WT mice are nice, but they do not bear on the brain region where this orphan receptor is important. Restoring GPR158 in neurons that normally make it in the PFC on a KO background and performing the behavioral and electrophysiological experiments would go a long way towards solidifying this story.

The current paper focuses on the role of Gpr158 in glutamatergic neurons. Here we have shown that the morphological changes induced by Gpr158 loss occur in glutamatergic neurons ([Figure 7A](#fig7){ref-type="fig"}) and the changes in synaptic strength and AMPA receptor function in Gpr158 KO also happen in glutamatergic neurons ([Figure 7E-I](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1B-C](#fig7s1){ref-type="fig"}). The identity of neurons examined in these experiments may not have been made clear and we have clarified this in the revision. Furthermore, we have added additional data to demonstrate the role of Gpr158 in glutamatergic neurons. In series of experiments we examined the cell-specific modulation of Gpr158 levels following chronic stress. We found that the increase in Gpr158 levels were only found in glutamatergic and not GABAergic neurons ([Figure 2](#fig2){ref-type="fig"}). We also investigated the changes in processing neurotransmitter inputs onto glutamatergic neurons obtained by patch clamping glutamatergic neurons specifically and recording their sEPSC ([Figure 7B-D](#fig7){ref-type="fig"}). Together, this demonstrates the role of Gpr158 action in glutamatergic neurons. We do not argue that Gpr158 in the GABAergic neurons may have an additional role in modulating behavioral outcomes but it is beyond the scope of this paper to examine this contribute in depth.

> The genetic background of the GPR158 WT and KO mice used here should be indicated. Were the WT and KO mice used for these studies littermates derived from breeding heterozygotes? If not, there is concern that WT and KO mice used for studies may have subtle genetic background differences.

The breeding strategy and genetic background has been clarified in the Materials and methods section. The mice were generated on a C57/BL6 background and were maintained as heterozygous breeding pairs to generate Gpr158^-/-^ and Gpr158^+/+^ mice that were used in the studies. We relied exclusively on littermates for all the comparisons.

> A recent study suggests that GPR158 is activated by osteocalcin (J Exp Med 214, 2859), that it participates in hippocampal memory and that it is coupled to G-α-q signaling. The results in this study do not seem to be compatible with G-α-q signaling.

Please see our response to major point \#5.

> Reviewer \#2:
>
> 1\) Over-expression is not directed to any cell type, so while the behavioral data is robust, it is challenging to interpret. Of additional concern, this is only explored in male mice. given later data in the KO mice was examined in males and female mice, seem like a useful comparison.

The reviewer is correct in that the over-expression of Gpr158 from the viral manipulations is not specific to any cell type. However, to address the concerns of cell-type specificity we have identified in which cell-type Gpr158 is affected following chronic stress. In these experiments mice were subjected to chronic stress and using in situ hybridization techniques we were able to quantify Gpr158 mRNA levels in glutamatergic and GABAergic neurons. We found that stress specifically regulates Gpr158 levels only in glutamatergic and not GABAergic neurons. This additional data can be found in [Figure 2](#fig2){ref-type="fig"}. We found that both male and female knockout mice showed the same phenotype in the behavioral assays (marble burying, elevated plus maze, tail suspension and force swim test) and as such the subsequent viral overexpression studies were only performed in male mice.

> 2\) The knockout data is compelling in such that deletion from birth can induce changes in behavior, synaptic function independent of stress exposure. This raises the issue that there could be a developmental compensation from the deletion of the receptor.
>
> Because of these issues, I think a more robust analysis would be a viral knockdown of GPR158 prior to stress exposure to parse out role of developmental deletion. These issues are not addressed in the manuscript, and given the novelty of these findings and the potential length of time it would take to repeat these experiments with a knockdown approach, I would also be favorable if there were a more in depth discussion of these concerns in the manuscript.

Like all studies involving transgenic mice there is always a concern that the deletion of a specific protein maybe due to a developmental compensation. However, the viral studies whereby we overexpressed Gpr158 in mPFC of adult mice ([Figure 4](#fig4){ref-type="fig"}) and rescued Gpr158 in the knockout model ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) of adult mice suggests that the behavioral effects are not due to developmental compensation from the lack of Gpr158. We have also addressed this issue in the Discussion.

> 3\) The authors present data showing that layer 2/3 neurons in the mPFC are altered. Given the expression of this protein in nearly all GABA neurons, this is an incomplete analysis. These particular experiments, recording from different cell types in KO and WT mice, would be very helpful in clarifying molecular/synaptic adaptations.

As suggested by the reviewer we have performed additional experiments directly recording from glutamatergic neurons in layer of 2/3 PFC. The results additionally corroborated our conclusions about alterations in the function of these neurons caused by GPR158 deletion and were incorporated in the revised manuscript ([Figure 7B-D](#fig7){ref-type="fig"}). For the reasons explained above (see responses to major points \#1 and \#2) we restricted our focus on studying glutamatergic neurons only.

> 4\) The near total exclusion of this GPCR in SST neurons is stunning. It is a bit confusing how the expression in GABA neurons is so high, but nothing in SST. It would be useful to flush this out a bit more with triple labeling, to provide further evidence of this selective expression.

We have addressed this concern in our response to the major point \#2.

> Reviewer \#3:
>
> 1\) It is important to validate the antibody used for immunofluorescence work in the KO mice. If it is selective, then the signal should not be detected in the PFC (or elsewhere) in the KO mice. It is understood that bands were not detected in KO tissues when using this antibody for immunoblotting. But, frequently antibodies that are relatively selective when used for immunoblotting will bind nonspecifically when used for immunoimaging.

The antibodies used were for Western blotting and have been thoroughly validated using KO tissues. The results showed the complete lack of the band that we consider to be Gpr158, thus confirming the specificity for this application. We did not use these antibodies for the immunohistochemistry because they produce diffuse neuropilar staining pattern (although specific) which does not allow easy attribution of cell specificity. Therefore, instead we have used the latest generation fluorescent in situ hybridization that provides sensitive detection of mRNA expression with high specificity and cellular resolution. The current manuscript may have not been sufficiently clear as to what technique we have used to characterize Gpr158 expression and we have since clarified this issue. In addition, we included control that establishes specificity of in situ hybridization reactions ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}).

> 2\) It appears from the presented immunoimaging that GPR158 is not cortically-enriched but rather expressed in most brain regions captured in the representative brain slice that is shown, with the exception of the white matter tracts as expected. This begs the question of whether GPR158 is active in other brain regions and if similar effects as those reported for the PFC in mice would have been detected when GPR158 expression is manipulated in other brain regions implicated in the regulation of depression-related behaviors, such as the hippocampus, accumbens etc. In other words, there are no anatomical controls in the current data-set to confirm that reported effects are anatomically selective. This is not a major issue, as the reported data are compelling, but some data related to other brain sites would have further strengthened the manuscript.

Gpr158 is indeed broadly expressed in the brain. To address regional specificity, we have analyzed Gpr158 protein levels following stress in other brain regions including nucleus accumbens, caudate/putamen, cerebellum and hippocampus ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). We only observed the upregulation of Gpr158 in the mPFC following chronic-stress exposure. While we cannot rule out the importance of Gpr158 in other brain regions, we can conclude that Gpr158 in the mPFC is sufficient to drive stress-mediated responses. We have also addressed this concept of regional specificity in the Discussion.

> 3\) Greater consideration should be given to the endogenous agonist for GPR158, and more broadly the likely signaling mechanisms for the receptor should be presented in the manuscript. I am not suggesting that the authors seek to de-orphanize the receptor as this is beyond the scope of this manuscript. However, is there any evidence from the published literature that hints at the identity of the endogenous agonist? Is GPR158 directly activated by glucocorticoids? To which intracellular signaling complex does GPR158 couple?

In the revised manuscript we provide evidence for signaling pathways engaged by Gpr158. We performed a screen looking at a variety of signaling molecules impacted by Gpr158 ablation in the PFC ([Figure 8A-B](#fig8){ref-type="fig"}). Most notably this includes the discovery that Gpr158 loss significantly upregulates neurotrophic factor BDNF and that this effect is mediated by changes in eEF2 phosphorylation which regulates local translation rather than affected by transcriptional upregulation ([Figure 8C-E](#fig8){ref-type="fig"}). Identification of BDNF as a signaling mediator of Gpr158 effects is exciting because it further mechanistically links signaling changes to observed changes in neuronal morphology as well as antidepressant effects that alter AMPA/NMDAR function, such as ketamine. We have also discussed possible endogenous agonists for Gpr158 and its possible region selective effects on signaling in the Discussion section.

[^1]: These authors contributed equally to this work.
